Concurrent Randomized, Double-Blind, Placebo-Controlled Trials to Validate Patient-Reported Outcome (PRO) Instruments and Assess Clinical Benefit of Treatment in Adults with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium AviumComplex (MAC)

TP96. TP096 CLINICAL AND BASIC SCIENCE DEVELOPMENTS IN NTM AND BRONCHIECTASIS Pub Date : 1900-01-01 DOI:10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a3947

C. Daley, J. Chalmers, P. Flume, D. E. Griffith, N. Hasegawa, K. Morimoto, K. Winthrop, D. Serrano, K. Mange, M. Hassan, D. Yuen, M. Ciesielska, Z. Jumadilova

引用次数: 0

查看原文本刊更多论文

同时进行随机、双盲、安慰剂对照试验，以验证患者报告的预后(PRO)仪器，并评估新诊断的非结核分枝杆菌(NTM)肺部感染由禽分枝杆菌复合物(MAC)引起的成人治疗的临床益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

TP96. TP096 CLINICAL AND BASIC SCIENCE DEVELOPMENTS IN NTM AND BRONCHIECTASIS

自引率

0.00%

发文量